LIQUIBOT automatically measures fluids given to and taken from patients after operations
Giving infusions and transfusions and measuring blood and other bodily fluids are essential to optimal patient care after an operation. Until now, medical staff had to measure these fluids manually most of the time.
Intelligent sensors and real-time data sharing to ensure top-quality care
LIQUIBOT, a recently founded subsidiary of Greiner Innoventures, is setting new standards in post-operative care by making it possible to record fluids digitally and in real time for use in for patient care. The combination of hardware and software includes an intelligent sensor to measure fluids and a real-time system that shares data with the hospital information system. For example, doctors can then see how post-operative bleeding changes after giving a certain medication and identify risk factors at an early stage. If fluids are balanced, patients can recover better and tend to be discharged more quickly.
“LIQUIBOT reduces healthcare bureaucracy and automates hospital processes. It allows us to create new diagnostic methods and improve patient healthcare in the long term,” said Michael Gröger, the operating managing director of LIQUIBOT.
From ideas competition to collaboration with OÖ Gesundheitsholding
The idea behind this innovation came about in 2018 as part of a hackathon run by Greiner Innoventures, i.e. a collaborative competition to develop new hardware and software solutions. The prototype created there was then further developed by Greiner Innoventures in collaboration with the Berlin-based provider Germantech and the Upper Austrian healthcare company, ultimately leading to the establishment of LIQUIBOT, another Greiner Innoventures subsidiary.
“The goal of Greiner Innoventures is to find solutions for current challenges and enable transformative innovations. Our aim with LIQUIBOT is to set new standards in data collection for post-operative fluid measurements and help shape hospitals’ digital transformation, said Hannes Möseneder, managing director of Greiner Innoventures.
Study with Kepler university hospital in Linz shows considerable potential
The added value brought by LIQUIBOT has already been successfully demonstrated in a practical trial at the Kepler University Hospital in Linz. A clinical trial is also currently underway to provide scientific evidence. The prototype quickly showed that it has considerable potential: As a first step, LIQUIBOT will be used primarily in intensive care units. In the future, LIQUIBOT could also be employed in general wards and in nephrology, for example to measure urine after kidney operations.
About Greiner Innoventures
Greiner Innoventures is Greiner’s innovation hub, working with startups as a corporate business angel to develop their ideas further. Greiner Innoventures looks where the future is happening and systematically implements these future issues in an entrepreneurial way. Greiner Innoventures is particularly active in innovative technologies in the areas of beyond plastic, circularity, last mile and digital care.